The JAK-inhibitor Ruxolitinib impairs dendritic cell function in vitro and in vivo

被引：0
|
作者：
Heine, A. [1 ]
Held, S. A. E. [1 ]
Daecke, S. N. [1 ]
Wallner, S. [2 ,3 ]
Yajnanarayana, S. P. [1 ]
Kurts, C. [4 ,5 ]
Wolf, D. [1 ]
Brossart, P. [1 ]
机构：
[1] Univ Klinikum Bonn, Bonn, Germany
[2] Univ Innsbruck Hosp, Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria
[3] Dept Med, Innsbruck, Austria
[4] Univ Bonn, Inst Mol Med, Bonn, Germany
[5] Univ Bonn, Inst Expt Immunol, Bonn, Germany
来源：
ONKOLOGIE | 2013年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：215 / 216
页数：2
相关论文
共 50 条
  • [31] The JAK1/JAK2-inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release
    Hermans, Maud A. W.
    Schrijver, Benjamin
    van Holten-Neelen, Conny C. P. A.
    Gerth van Wijk, Roy
    van Hagen, P. Martin
    van Daele, Paul L. A.
    Dik, Willem A.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2018, 48 (11): : 1412 - 1420
  • [32] Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer
    DeMichele, A. M.
    Clark, A. S.
    Holmes, R.
    Volpe, M.
    Medrano, C.
    Troxel, A.
    Fox, K.
    Domchek, S.
    Matro, J.
    Bradbury, A.
    Shih, N.
    Feldman, M.
    Hexner, E.
    Bromberg, J.
    CANCER RESEARCH, 2017, 77
  • [33] JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa
    Boor, Patrick P. C.
    De Ruiter, Petra E.
    Asmawidjaja, Patrick S.
    Lubberts, Erik
    van der Laan, Luc J. W.
    Kwekkeboom, Jaap
    TRANSLATIONAL RESEARCH, 2017, 188 : 67 - 79
  • [34] JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
    Schoenberg, Kathrin
    Rudolph, Janna
    Vonnahme, Maria
    Yajnanarayana, Sowmya Parampalli
    Cornez, Isabelle
    Hejazi, Maryam
    Manser, Angela R.
    Uhrberg, Markus
    Verbeek, Walter
    Koschmieder, Steffen
    Bruemmendorf, Tim H.
    Brossart, Peter
    Heine, Annkristin
    Wolf, Dominik
    CANCER RESEARCH, 2015, 75 (11) : 2187 - 2199
  • [35] In vivo enhancement of dendritic cell function
    Bilsborough, J
    Viney, JL
    ORAL TOLERANCE: NEW INSIGHTS AND PROSPECTS FOR CLINICAL APPLICATION, 2004, 1029 : 83 - 87
  • [36] Administration of α-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo
    Simkins, Helen M. A.
    Hyde, Evelyn
    Farrand, Kathryn J.
    Ong, Monique L.
    Degli-Esposti, Mariapia A.
    Hermans, Ian F.
    Ronchese, Franca
    JOURNAL OF LEUKOCYTE BIOLOGY, 2011, 89 (05) : 753 - 762
  • [37] Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo
    Hackstein, H
    Taner, T
    Zahorchak, AF
    Morelli, AE
    Logar, AJ
    Gessner, A
    Thomson, AW
    BLOOD, 2003, 101 (11) : 4457 - 4463
  • [38] Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
    N Jaekel
    G Behre
    A Behning
    C Wickenhauser
    T Lange
    D Niederwieser
    H K Al-Ali
    Bone Marrow Transplantation, 2014, 49 : 179 - 184
  • [39] Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
    Jaekel, N.
    Behre, G.
    Behning, A.
    Wickenhauser, C.
    Lange, T.
    Niederwieser, D.
    Al-Ali, H. K.
    BONE MARROW TRANSPLANTATION, 2014, 49 (02) : 179 - 184
  • [40] Ethanol alters dendritic cell function in vivo and impairs the subsequent cellular immune responses to hepatitis C
    Aloman, C
    Gehring, S
    Wands, JR
    HEPATOLOGY, 2005, 42 (04) : 568A - 569A
12345